IP Library Granted Patent US 8,283,454
Granted Patent B2
US 8,283,454 · App. 12/545,400 · Granted Oct 9, 2012

Processes for the preparation of SGLT2 inhibitors

Assignee: Theracos, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,283,454
App. No.
12/545,400
Granted
Oct 9, 2012
Kind
B2
Abstract

Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.

Claims (54)

1. A method for the preparation of a complex of Formula IA:

wherein the subscript n is 1 or 2;

R 1 is a member selected from the group consisting of hydrogen, halo and C 1 -C 6 alkyl;

V is a member selected from the group consisting of oxygen and a single bond;

W is a member selected from the group consisting of C 1 -C 6 alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, C 3 -C 10 cycloalkylene, and (C 3 -C 10 cycloalkylene)(C 1 -C 6 alkylene) wherein the C 3 -C 10 cycloalkylene portion bonds to V and the C 1 -C 6 alkylene portion bonds to X;

X is a member selected from the group consisting of oxygen and NR a ;

Y is a member selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 6 hydroxyalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, (C 3 -C 10 cycloalkyl)C 1 -C 4 alkyl, (C 1 -C 4 alkyloxy)C 1 -C 3 alkyl, (C 3 -C 10 cycloalkyloxy)C 1 -C 3 alkyl, (amino)C 1 -C 3 alkyl, (C 1 -C 4 alkylamino)C 1 -C 3 alkyl, (C 1 -C 6 alkyl)carbonyl, (C 2 -C 6 alkenyl)carbonyl, (C 2 -C 6 alkynyl)carbonyl, (C 1 -C 6 alkyl)sulfonyl, (C 2 -C 6 alkenyl)sulfonyl, and (C 2 -C 6 alkynyl)sulfonyl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of W, X and Y are optionally partly or completely fluorinated and are optionally mono- or disubstituted by substituents independently selected from the group consisting of chlorine, hydroxy, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, and C 3 -C 6 cycloalkyl, and in cycloalkyl groups or portions one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO 2 or NR b , and one or two methyne groups are optionally replaced by N, wherein the heterocycle formed by said optional replacement is other than heteroaryl; and

R a is a member independently selected from the group consisting of H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and (C 1 -C 4 alkyl)carbonyl, wherein alkyl and cycloalkyl groups or portions are optionally partly or completely fluorinated;

each R b is a member independently selected from the group consisting of H, C 1 -C 4 alkyl and (C 1 -C 4 alkyl)carbonyl, wherein alkyl groups or portions are optionally partly or completely fluorinated;

and pharmaceutically acceptable salts thereof;

comprising:

(a) reacting a compound of Formula II

with a reducing agent in the presence of an activating group to form a compound of Formula III

and

(b) contacting said compound of Formula III with an amino acid to form said complex of Formula IA;

wherein steps (a) and (b) are performed without purification of said compound of Formula III and wherein steps (a) and (b) are performed sequentially without an intervening protection or deprotection step.

2. A method in accordance with claim 1 , wherein said process is conducted in a single reaction vessel.

3. A method in accordance with claim 2 , wherein said complex of Formula IA is isolated as a crystalline solid.

4. A method in accordance with claim 1 , wherein X is oxygen.

5. A method in accordance with claim 4 , wherein Y is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl and (C 1 -C 4 alkyloxy)C 1 -C 3 alkyl.

6. A method in accordance with claim 5 , wherein R 1 is halo.

7. A method in accordance with claim 1 , wherein said reducing agent is an alkylsilyl hydride and the activating agent is a Lewis acid.

8. A method in accordance with claim 7 , wherein said reducing agent is triethylsilane and said Lewis acid is BF 3 .Et 2 O.

9. A method in accordance with claim 1 , wherein step (a) is carried out in a solvent or solvent mixture comprising a member selected from the group consisting of acetonitrile and dichloromethane.

10. A method in accordance with claim 1 , wherein step (b) is carried out in a solvent or solvent mixture comprising a member selected from the group consisting of ethanol, water and hexane.

11. A method in accordance with claim 1 , wherein step (a) is carried out in a solvent or solvent mixture comprising a member selected from the group consisting of acetonitrile and dichloromethane, and step (b) is carried out in a solvent or solvent mixture comprising a member selected from the group consisting of ethanol, water and hexane.

12. A method for the preparation of a complex of Formula IA:

wherein the subscript n is 1 or 2;

R 1 is chloro;

the group —V—W—X—Y is selected from the group consisting of:

2-(2 methoxyethoxy)ethoxy;

2-(allyloxy)ethoxy;

2-(prop-2-ynyloxy)ethoxy;

1-(prop-2-ynyloxy)propan-2-yloxy;

4-hydroxybut-2-ynyloxy;

4 methoxybut-2-ynyloxy;

2-(cyclopentyloxy)ethoxy;

3-cyclopropylprop-2-ynyloxy;

2-(difluoromethoxy)ethyl;

2-cyclopropoxyethoxy;

2-(2,2,2-trifluoroethoxy)ethoxy;

2-(cyclohex-2-enyloxy)ethoxy; and

(E)-3-cyclopropylallyloxy);

comprising:

(a) reacting a compound of Formula II

with a reducing agent in the presence of an activating group to form a compound of Formula III

and

(b) contacting said compound of Formula III with an amino acid to form said complex of Formula IA;

wherein steps (a) and (b) are performed without purification of said compound of Formula III and wherein steps (a) and (b) are performed sequentially without an intervening protection or deprotection step.

13. A method in accordance with claim 1 wherein said amino acid is selected from the group consisting of proline and phenylalanine.

14. A method in accordance with claim 12 , wherein said amino acid is proline and the subscript n is 2.

15. A method in accordance with claim 12 wherein said amino acid is selected from the group consisting of proline and phenylalanine.

16. A method in accordance with claim 15 , wherein said amino acid is proline and the subscript n is 2.

Assignments (5)
CHANGE OF NAME Recorded Jan 10, 2023
From: THERACOS SUB, LLC
To: THERACOSBIO, LLC
Reel/Frame 062351/0605 →
SECURITY INTEREST Recorded Jan 19, 2016
From: THERACOS SUB, LLC
To: SEED, BRIAN
Reel/Frame 037522/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2015
From: THERACOS, INC.
To: THERACOS SUB, LLC
Reel/Frame 035760/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2010
From: LIOU, JASON; WU, YUELIN; LI, SHENGBIN; XU, GE
To: THERACOS, INC.
Reel/Frame 024214/0055 →
SECURITY AGREEMENT Recorded Mar 25, 2010
From: THERACOS, INC.
To: SEED, BRIAN
Reel/Frame 024139/0854 →
Continuity (2)
Provisional Application 61091248 · Aug 22, 2008
Related Publication 20100222599A1 · Sep 2, 2010